The American Journal of Medicine
Volume 123, Issue 2 , Pages 141-150 , February 2010

Variations in Perioperative Warfarin Management: Outcomes and Practice Patterns at Nine Hospitals

  • Amir K. Jaffer, MD

      Affiliations

    • Division of Hospital Medicine, Leonard M. Miller School of Medicine, University of Miami, Fla
    • ,
  • Daniel J. Brotman, MD

      Affiliations

    • Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Md
    • Corresponding Author InformationReprint requests should be addressed to Daniel J. Brotman, MD, FACP, FHM, Director, Hospitalist Program, Johns Hopkins Hospital Park 307, 600 North Wolfe St, Baltimore, MD 21287
    • ,
  • Lori D. Bash, PhD

      Affiliations

    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md
    • ,
  • Syed K. Mahmood, MD

      Affiliations

    • Department of Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Brooke Lott, BA

      Affiliations

    • Division of General Internal Medicine, University of California at Davis
    • ,
  • Richard H. White, MD

      Affiliations

    • Division of General Internal Medicine, University of California at Davis

References 

  1. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163:901–908
  2. Jaffer AK, Brotman DJ, Chukwumerije N. When patients on warfarin need surgery. Cleve Clin J Med. 2003;70:973–984
  3. Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves (A prospective study). Am Heart J. 1978;96:163–165
  4. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the prospective perioperative enoxaparin cohort trial (PROSPECT). J Thromb Haemost. 2007;5:2211–2218
  5. Manley HJ, Smith JA, Garris RE. Subcutaneous enoxaparin for outpatient anticoagulation therapy in a patient with an aortic valve replacement. Pharmacotherapy. 1998;18:408–412
  6. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses (Observations in 180 operations). JAMA. 1978;239:738–739
  7. Carrel TP, Klingenmann W, Mohacsi PJ, et al. Perioperative bleeding and thromboembolic risk during non-cardiac surgery in patients with mechanical prosthetic heart valves: an institutional review. J Heart Valve Dis. 1999;8:392–398
  8. Spandorfer JM, Lynch S, Weitz HH, et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999;84:478–480A10
  9. Tinmouth AH, Morrow BH, Cruickshank MK, et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 2001;35:669–674
  10. Ferreira I, Dos L, Tornos P, et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart. 2003;89:527–530
  11. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319–1326
  12. Spyropoulos AC, Turpie AG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006;4:1246–1252
  13. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110:1658–1663
  14. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006;114:e84–e231
  15. Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med. 2003;163:881–883
  16. Kearon C, Hirsh J. Perioperative management of patients receiving oral anticoagulants. Arch Intern Med. 2003;163:2532–2533author reply 2533
  17. Spandorfer J. The management of anticoagulation before and after procedures. Med Clin North Am. 2001;85:1109–1116
  18. Spyropoulos AC, Jenkins P, Bornikova L. A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation. Pharmacotherapy. 2004;24:649–658
  19. Jaffer AK. Issues in anticoagulant therapy: recent trials start to answer the tough questions. Cleve Clin J Med. 2005;72:157–163
  20. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending (Part 1: the content, quality, and accessibility of care). Ann Intern Med. 2003;138:273–287
  21. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315–328
  22. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–99
  23. Pasternak LR. Preoperative assessment of the ambulatory and same-day admission patient. Wellcome Trend Anesthesiol. 1991;9:3–11
  24. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281
  25. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168:63–69

 Funding: This study was funded by an investigator sponsored grant from Astra-Zeneca International. Additional funding was provided by the Johns Hopkins Hospitalist Scholars Program.

 Conflict of Interest: Dr Jaffer has received a research grant from Astra Zeneca and served as a consultant to Astra Zeneca. Dr White has received funding from Astra-Zeneca International for other investigator-initiated studies. All other authors have no conflicts of interest to declare.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)00947-4

doi: 10.1016/j.amjmed.2009.09.017

The American Journal of Medicine
Volume 123, Issue 2 , Pages 141-150 , February 2010

Article Tools

* Image Usage & Resolution